Literature DB >> 30819401

Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population.

Luai R Zarour1, Kevin G Billingsley2, Brett S Walker1, C Kristian Enestvedt3, Susan L Orloff3, Erin Maynard3, Skye C Mayo4.   

Abstract

BACKGROUND: Management of elderly patients with solitary hepatocellular carcinoma (sHCC) is challenging with perceived clinicopathologic differences driving treatment options. We sought to determine factors predictive of disease control and survival after hepatic resection of sHCC in elderly patients.
METHODS: We identified n = 45 elderly patients (³≥65 yo) with sHCC treated with hepatic resection alone from our prospective database from 2003-16. Clinicopathologic data were analyzed and survival was assessed from the time of hepatic resection.
RESULTS: The median age was 75-years-old. Less than half of patients (47%) had viral hepatitis. At resection, the median Child-Pugh score was A6, median tumor size 5 cm, and mean AFP of 1050 (ng/mL). Major hepatectomy was performed in 23 patients (51%) with R0 resection achieved in 96%. Two patients (4%) had Grade III complications with no mortalities at 30 days and one death (2%) at 90-days. After R0 resection 44% (n = 20) had intrahepatic recurrence at a median of 32 months (95% CI: 15-46) with 20% (n = 9) developing extrahepatic recurrence at a median of 78 months (95% CI: 78-.). The median survival was 72 months (95% CI: 30-108 months). For patients with at least 3 years of follow-up, the 1-, 3-, and 5-year overall survival was 74%, 59%, and 50%, respectively. Mortality was associated with higher AFP and lower Prognostic Nutritional Index (PNI).
CONCLUSION: Carefully selected elderly patients with sHCC appear to have unique disease that is amenable to hepatic resection with low morbidity and mortality with excellent overall and recurrence-free survival.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 30819401     DOI: 10.1016/j.amjsurg.2019.01.030

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  6 in total

1.  Safety and Feasibility of Microwave Ablation for Hepatocellular Carcinomas in the Elderly: A Systematic Review.

Authors:  Weiren Liang; Weiyuan Hao; Guoliang Shao; Jiaping Zheng; Hui Zeng; Danping Zhou; Hefeng Yao
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

2.  Outcomes of Geriatric Patients with Hepatocellular Carcinoma.

Authors:  Chern-Horng Lee; Tzung-Hai Yen; Sen-Yung Hsieh
Journal:  Curr Oncol       Date:  2022-06-16       Impact factor: 3.109

3.  Hepatocellular carcinoma in old age: are there any benefits of liver resection in old age?

Authors:  In Sik Shin; Deok Gie Kim; Sung Whan Cha; Seong Hee Kang; Sung Hoon Kim; Moon Young Kim; Soon Koo Baik
Journal:  Ann Surg Treat Res       Date:  2020-07-31       Impact factor: 1.859

4.  Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers.

Authors:  Dominik Safcak; Sylvia Drazilova; Jakub Gazda; Igor Andrasina; Svetlana Adamcova-Selcanova; Lea Balazova; Radovan Barila; Michal Mego; Marek Rac; Lubomir Skladany; Miroslav Zigrai; Martin Janicko; Peter Jarcuska
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

5.  Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?

Authors:  Lukas Müller; Felix Hahn; Aline Mähringer-Kunz; Fabian Stoehr; Simon J Gairing; Friedrich Foerster; Arndt Weinmann; Peter R Galle; Jens Mittler; Daniel Pinto Dos Santos; Michael B Pitton; Christoph Düber; Roman Kloeckner
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

6.  Feasibility and safety of surgical microwave ablation for hepatocellular carcinoma in elderly patients: a single center analysis in Japan.

Authors:  Hajime Imamura; Yuko Takami; Tomoki Ryu; Yoshiyuki Wada; Shin Sasaki; Hiroki Ureshino; Hideki Saitsu
Journal:  Sci Rep       Date:  2020-08-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.